期刊
JOURNAL OF NEUROCHEMISTRY
卷 127, 期 5, 页码 681-690出版社
WILEY
DOI: 10.1111/jnc.12331
关键词
alpha-synuclein; Alzheimer's disease; biomarkers; cerebrospinal fluid; dementia with Lewy bodies; VILIP-1
资金
- Chinese National Science Foundation [30970902]
- Guangdong Science and Technology Program [2010B031600018]
- Guangzhou Science and Technology Program [2010Y1-C631]
The overlapping clinical features of Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB) make differentiation difficult in the clinical environment. Evaluating the CSF levels of biomarkers in AD and DLB patients could facilitate clinical diagnosis. CSF Visinin-like protein-1 (VILIP-1), a calcium-mediated neuronal injury biomarker, has been described as a novel biomarker for AD. The aim of this study was to investigate the diagnostic utility of CSF VILIP-1 and VILIP-1/A(1-42) ratio to distinguish AD from DLB. Levels of CSF VILIP-1, t-tau, p-tau(181P), A(1-42), and -synuclein were measured in 61 AD patients, 32 DLB patients, and 40 normal controls using commercial ELISA kits. The results showed that the CSF VILIP-1 level had significantly increased in AD patients compared with both normal controls and DLB patients. The CSF VILIP-1 and VILIP-1/A(1-42) levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. Additionally, CSF VILIP-1 levels were positively correlated with t-tau and p-tau(181P) within each group and with -synuclein in the AD and control groups. We conclude that CSF VILIP-1 could be a diagnostic marker for AD, differentiating it from DLB. The analysis of biomarkers, representing different neuropathologies, is an important approach reflecting the heterogeneous features of AD and DLB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据